Literature DB >> 32147090

Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation.

Harun Kundi1, Peter A Noseworthy2, Linda R Valsdottir1, Changyu Shen1, Xiaoxi Yao3, Robert W Yeh1, Daniel B Kramer4.   

Abstract

Catheter ablation for atrial fibrillation (AF) improves outcomes compared with medical treatment alone. Risk stratification for outcomes following AF ablation remains an important area of uncertainty. This analysis evaluated the association between frailty and outcomes following AF ablation. We evaluated US inpatients receiving AF ablation between January 1, 2016 and December 1, 2016 using Medicare fee-for-service billing codes. Diagnosis codes were used to calculate patients' Hospital Frailty Risk Score, with the cohort divided according to established cut-points of low (<5), intermediate (5 to 15), and high (>15) risk for frailty. The primary outcome was survival. Among 5,070 in patients treated with catheter ablation (mean age 74.9 ± 6.8 years, 51.1% female), 38.6% were defined as frail with a Hospital Frailty Risk Score >5, including 8.3% at high risk. Mortality rates (up to 630 days) were 5.8% in the low-risk group, 23.4% in the intermediate-risk group, and 42.2% in the high-risk group (log-rank p values <0.001 for comparison between categories). In restricted cubic spline regression analysis, the adjusted hazard ratios for long-term mortality monotonically increased with increasing values of the Hospital Frailty Risk Score (adjusted hazard ratio 1.065, 95% confidence interval 1.054 to 1.077). In secondary end points, frailty was independently associated with length of stay, postprocedure 30-day mortality, 30-day readmission and postdischarge 30-day mortality rates. In conclusion, frailty as assessed by a claims-based score is common in inpatient recipients of AF ablation, and provides risk stratification for mortality and other key clinical outcomes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32147090     DOI: 10.1016/j.amjcard.2020.01.049

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Catheter ablation for atrial fibrillation: current indications and evolving technologies.

Authors:  Ramanathan Parameswaran; Ahmed M Al-Kaisey; Jonathan M Kalman
Journal:  Nat Rev Cardiol       Date:  2020-10-13       Impact factor: 32.419

2.  The use of linked routine data to optimise calculation of the Hospital Frailty Risk Score on the basis of previous hospital admissions: a retrospective observational cohort study.

Authors:  Andrew Street; Laia Maynou; Thomas Gilbert; Tony Stone; Suzanne Mason; Simon Conroy
Journal:  Lancet Healthy Longev       Date:  2021-03

3.  Prognostic value of geriatric conditions for death and bleeding in older patients with atrial fibrillation.

Authors:  Weijia Wang; Darleen Lessard; Jane S Saczynski; Robert J Goldberg; Jordy Mehawej; Ely Gracia; David D McManus
Journal:  Int J Cardiol Heart Vasc       Date:  2021-03-04

4.  Incident frailty and cognitive impairment by heart failure status in older patients with atrial fibrillation: the SAGE-AF study.

Authors:  Wei-Jia Wang; Darleen Lessard; Jane Saczynski; Robert J Goldberg; Alan S Go; Tenes Paul; Ely Gracia; David D McManus
Journal:  J Geriatr Cardiol       Date:  2020-11-28       Impact factor: 3.327

5.  Analysis of Frailty in Geriatric Patients as a Prognostic Factor in Endovascular Treated Patients with Large Vessel Occlusion Strokes.

Authors:  Marlena Schnieder; Mathias Bähr; Mareike Kirsch; Ilko Maier; Daniel Behme; Christian Heiner Riedel; Marios-Nikos Psychogios; Alex Brehm; Jan Liman; Christine A F von Arnim
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

6.  Beyond the revised cardiac risk index: Validation of the hospital frailty risk score in non-cardiac surgery.

Authors:  Pishoy Gouda; Xiaoming Wang; Erik Youngson; Michael McGillion; Mamas A Mamas; Michelle M Graham
Journal:  PLoS One       Date:  2022-01-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.